Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Date:9/29/2010

MOUNTAIN VIEW, Calif., Sept. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of its underwritten registered offering of 3,000,000 shares of its common stock at an offering price of $14.50 per share.  Net offering proceeds, after estimated underwriting discounts and commissions and other estimated offering expenses, will be approximately $40.9 million, assuming no exercise by the underwriters of their over-allotment option.  MAP Pharmaceuticals has granted the underwriters of the offering a thirty (30) day option to purchase up to 450,000 additional shares to cover over-allotments, if any.  MAP Pharmaceuticals intends to use the proceeds from this offering for the development of LEVADEX and for general corporate purposes.  MAP Pharmaceuticals expects the offering to close on or about October 4, 2010, subject to customary closing conditions.  Lazard Capital Markets LLC is acting as the sole book-running manager and Wedbush PacGrow Life Sciences as the co-manager for the offering.

MAP Pharmaceuticals has filed a shelf registration statement on Form S-3 and an accompanying prospectus with the Securities and Exchange Commission ("SEC"), which was declared effective by the SEC.  A prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement.  When available, copies of the preliminary prospectus supplement, the final prospectus supplement and accompanying base prospectus related to this offering may be obtained from the SEC's website at http://www.sec.gov or Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (800) 542-0970.

This press release shall not constitute an offer to sell or the solicitation of offers to buy any securities of MAP Pharmaceuticals and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, available at http://edgar.sec.gov. CONTACTS:Nicole FoderaroWCG(415) 946-1058 nfoderaro@wcgworld.comCopyright (C) 2010 PR Newswire. All rights reserved


'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 A recent research report published by ... alone is expected to reach a value of $55.8 billion by ... with 28 states have legalized marijuana for medical uses. In 2016, ... , North Dakota , Ohio ... use the drug in medical applications such as chemotherapies and pain ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result ... share (-0.22) before and after dilution Cash flow from operating ... ... SEK 0.4 (0.4) million Operating result amounted to SEK -39.5 ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 2017 , ... Functional imaging data supports improved cognition in ... today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , It ... improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et al., ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to sharpen ... With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal ... color spectrum tools users can visually see the color range effected with ease all ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , ... office, Antoine Dental Center. Currently, patients can get single dental implants for $3,599 ... patients can learn more about these offers by contacting Antoine Dental Center. Both ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provides business development, education, networking and recognition opportunities as well as advocacy for ... Works in Holmdel, NJ on February 23. The Council's Innovation Forecast event ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... University, has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, ... Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the ...
Breaking Medicine News(10 mins):